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Abstract. Poor quality antimalarials, including falsified, substandard, and degraded drugs, are a serious health concern
in malaria-endemic countries. Guidelines are lacking on how to distinguish between substandard and degraded drugs.
“Forced degradation” in an oven was carried out on three common artemisinin-based combination therapy (ACT) brands
to detect products of degradation using liquid chromatography mass spectrometry and help facilitate classification of
degraded drugs. “Natural aging” of 2,880 tablets each of ACTs artemether/lumefantrine and artesunate/amodiaquine was
undertaken to evaluate their long-term stability in tropical climates. Samples were aged in the presence and absence of
light on-site in Ghana and in a stability chamber (London), removed at regular intervals, and analyzed to determine loss of
the active pharmaceutical ingredients (APIs) over time and detect products of degradation. Loss of APIs in naturally aged
tablets (both in Ghana and the pharmaceutical stability chamber) was 0–7% over 3 years (∼12 months beyond expiry)
with low levels of degradation products detected. Using this developed methodology, it was found that a quarter of ACTs
purchased in Enugu, Nigeria (concurrent study), that would have been classified as substandard, were in fact degraded.
Presence of degradation products together with evidence of insufficient APIs can be used to classify drugs as degraded.
BACKGROUND
Malaria, caused by parasites of the genus Plasmodium, is a
major public health burden in the tropics resulting in 584,000
deaths in 2013.1 Artemisinin-based combination therapies
(ACTs,) are the mainstay of the treatment used in the major-
ity of malaria-endemic countries and have greatly contributed
to the reduction in malaria morbidity and mortality.2
Artemisinin is extracted from the plant Artemisia annua, gen-
erally known as sweet wormwood.3,4 Chemical derivatives of
artemisinin (artesunate [AS], artemether [AM], and dihydro-
artemisinin [DHA]) are combined with a partner drug such
as amodiaquine (AQ), lumefantrine (LUM), or piperaquine
(PIP) to form currently used ACTs: AS/AQ, AM/LUM, and
DHA/PIP.5,6
Efficacious malaria control and treatment necessitates the
use of good quality medication that contains the required
dose of active pharmaceutical ingredients (APIs). Studies
predominantly in Africa and southeast Asia have suggested
that a significant proportion of ACTs are of poor quality,7–10
which poses a threat to malaria patients as a result of ineffec-
tual treatment11 and could facilitate the emergence and spread
of drug-resistant parasites.12 Poor quality drugs include sub-
standard drugs (these contain either less than or more than
the acceptable dose of APIs as a result of poor manufacturing
practices), falsified (also referred to as counterfeit or spurious
medicines; do not contain the stated APIs and may carry false
representation of their source of identity) and degraded for-
mulations.13,14 Degraded drugs are defined as good quality
formulations that are degraded by storage in the presence of
heat, light, and humidity after they leave the manufacturer.
Factors postulated to contribute to the degradation of a drug
include ambient temperature, moisture, light, microbes, pack-
aging materials, transportation conditions, and the nature of
the active ingredients and excipients.15
The assessment of the prevalence of substandard medicines
is hindered by the lack of information regarding the stability
of medicines that may have been of acceptable quality when
released by the manufacturer and have since deteriorated
during transportation. Of concern is the intrinsic stability of
artemisinin derivatives under conditions of high temperature
and humidity, typical in tropical countries where malaria is
endemic.16,17 The International Conference on Harmonization
(ICH) and the World Health Organization (WHO) state that to
fully assess the long-term stability of finished pharmaceutical
products, testing should be conducted during and beyond the
expected shelf life and storage conditions experienced in the
intended market.18 The ICH and WHO divide the globe into cli-
matic zones depending on the prevailing annual temperature and
humidity conditions, which includes the majority of malaria-
endemic countries in climatic zone IV as they experience both
hot and humid conditions (mean annual temperature > 22°C and
relative humidity of > 45%), for which recommended conditions
for stability testing are a minimum of 12 months.18 Stability test-
ing by the manufacturer, however, may not reflect the actual
range of temperature and humidity in uncontrolled conditions
in Africa and southeast Asia. To address this, we assess the long-
term stability of ACTs Coartem® (AM/LUM; Novartis, China)
and Winthrop® (AS/AQ; Sanofi-Aventis, Morocco) over a
3-year “natural aging” study in tropical climatic conditions.
Although substandard drugs can be defined as those that
do not meet the pharmacopeia-specified limits on API con-
tent, there is no established method to objectively classify
drugs as degraded. Hence, in this study we aimed to develop
an analytical methodology to detect the fingerprint of the
degradation product profile using liquid chromatography
mass spectrometry (LC–MS). “Forced degradation” of three
common ACTs was carried out, and the degradation product
profile was compared with drug samples after natural aging.
Our findings were then used to distinguish between substan-
dard and degraded ACT tablets purchased in Enugu, Nigeria.19
METHODS
Forced degradation studies. Three of the most common
ACT formulations, 42 tablets in seven blister packs each
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of Coartem (AM/LUM), Winthrop (AS/AQ), and Waipa
(DHA/PIP) were subjected to forced degradation15,20,21 in
an oven set at 60°C for up to 21 days (Table 1). Half the
blister packs were placed in the oven intact, whereas the other
half were perforated before placement in the oven; degrada-
tion rates were compared for the two groups. Six tablets in
blisters (three perforated, three intact) were removed twice
per week for 3 weeks.
Natural aging studies. The long-term stability of Coartem
(AM/LUM) and Winthrop (AS/AQ) tablets was investigated
in a natural aging study over 3 years by storing the tablets
as intact and perforated blister packs in the presence and
absence of light at tropical temperature and humidity (Table 1
and Figure 1). Tablets were stored in their original packaging
(blister pack and box) inside a drawer (dark) or on a shelf (light)
at Kintampo Health Research Center, Ghana, and in the phar-
maceutical stability chamber (PSC022.AHX; Weiss Gallenkamp
Ltd., United Kingdom) at the London School of Hygiene
and Tropical Medicine (LSHTM; Supplemental Figure 1).
The temperature and humidity conditions on the stability
chamber were reset on a monthly basis to correspond to field
conditions recorded in Kintampo, Ghana. Over the 3 years,
median temperature in Ghana was 33°C ± 5°C with a relative
humidity of 55% ± 20% (typical conditions). Stability of the
ACTs was determined by measuring and comparing the loss
of APIs, at predetermined intervals over a 3-year period,
in line with the guidelines issued by the ICH for long-term
stability testing.22
A total of 2,880 tablets of each formulation were selected
to be aged at the two sites (Figure 1), each divided into four
storage groups (light perforated, light intact, dark perforated,
and dark intact). At defined time points (0, 3, 6, 9, 12, 18, 24,
30, and 36 months), a total of 144 tablets of each formulation
were removed from each site and stored in their blister packs
at 4°C before analysis at the end of the study. All aged tab-
lets were analyzed together at the end of the study to mini-
mize variability in the data from changes in chromatographic
conditions, and tablets at aging time 0 were used as refer-
ence. Thus, for each formulation, there were 36 replicates
per storage treatment and time point, allowing a comparison
between group means with a power of 80%, α = 0.05 (assum-
ing a difference in group means of at least 3%, σ = 5%).
The null hypothesis was that the API content in tablets after
36 months was not significantly different from the amount
present in tablets at time 0 and that there were no significant
differences between the storage groups or the condition of
the packaging, that is, blister intact or perforated. Each drug
was analyzed separately, and the average API content at the
start of the study was compared with that after 36 months,
under each of the different storage conditions, by one-way
analysis of variance (ANOVA, α = 0.05). Further tests, where
warranted, were performed using Tukey’s honestly significant
difference (HSD) post hoc tests.
Chromatographic analyses. The amounts of the stated APIs in
the ACT tablets were quantified using high-performance liquid
chromatography photo diode array (HPLC–PDA). In brief, whole
TABLE 1
Study details for “forced degradation” and “natural aging” of artemisinin-based combination therapies
Location of study Formulation and manufacturer Manufacture information
Forced degradation
60°C oven (LSHTM)
Study date October 2013 to December 2013
Winthrop® (100 mg AS/270 mg AQ)
Sanofi-Aventis Group, Maphar Laboratories, Morocco
Lot 5491
Expiry: May 2015
Coartem® (20 mg AM/120 mg LUM)
Novartis, China
Lot X1607
Expiry: September 2014
Waipa (30 mg DHA/225 mg PIP)
Kunimed Pharmachem Ltd., Nigeria
Lot SFH08
Expiry: December 2013
Natural aging
Ghana (KHRC)
Study date January 2011 to January 2014
Winthrop® (100 mg AS/270 mg AQ)
Sanofi-Aventis Group, Maphar Laboratories, Morocco
Lot 5186
Expiry: June 2012
Coartem® (20 mg AM/120 mg LUM)
Novartis, China
Lot X1448
Expiry: December 2012
Stability chamber (LSHTM) Winthrop® (100 mg AS/270 mg AQ)
Sanofi-Aventis Group, Maphar Laboratories, Morocco
Lot 5186
Expiry: June 2012
Coartem® (20 mg AM/120 mg LUM)
Novartis, China
Lot X1448
Expiry: December 2012
AM = artemether; AS = artesunate; AQ = amodiaquine; DHA = dihydroartemisinin; KHRC = Kintampo Health Research Center; LSHTM = London School of Hygiene and Tropical
Medicine; LUM = lumefantrine; PIP = piperaquine.
FIGURE 1. Study design for “natural aging” of ACTs. Herein, 2,880 tablets each of Coartem® AM/LUM and Winthrop® AS/AQ were stored
for 36 months in two sites, Ghana (KHRC) and a stability chamber in London (LSHTM), in the presence and absence of light and with intact or
perforated blister packs. Temperature and humidity settings in the stability chamber were adjusted on a monthly basis to the average ambient
conditions in Ghana (33°C ± 5°C, relative humidity = 55% ± 20%). ACTs = artemisinin-based combination therapies; AM/LUM = artemether/
lumefantrine; AS/AQ = artesunate/amodiaquine; KHRC = Kintampo Health Research Center.
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tablets were pulverized and dissolved in methanol to give a final
statedAPI (AM,AS, andDHA) concentration of 10 mg/mL and
analyzed following our published method.19 Quantitative analyses
were carried out using Dionex Ultimate 3000 HPLC–PDA
system (Thermo Fisher, Hemel Hempstead, United Kingdom),
and separation was achieved using a GENESIS® AQ 4-μm
column (150 × 4.6 mm; Grace Materials Technologies, Carnforth,
United Kingdom).23 Quality-assured APIs were used for the
calibration plots; AS and AQ were a gift from Sanofi-Aventis
Group (Gentilly Cedex, France), and AM and LUM were a
gift from Novartis Pharma AG (Basel, Switzerland).
The LC–MS method was developed to obtain the chro-
matographic “fingerprint” or “profile” of the drug(s) and
their specific degradation products using Dionex Ultimate
3000 LC system coupled to Thermo Finnigan LCQ Advantage
(Thermofisher). Samples were separated on a Dionex Acclaim
120 3-μm C18 column (4.6 × 150 mm) with isocratic elution
at a flow rate of 1 mL/minute. Mobile phase for AM/LUM
consisted of 90/10 (v/v) methanol/ammonium formate buffer
(10 mM, pH 2.7), AS/AQ required 65/35 (v/v) acetonitrile/
ammonium formate buffer, and DHA/PIP samples were eluted
with 75/25 (v/v) methanol/ammonium formate buffer. Ions were
generated by electrospray ionization and the mass spectrome-
ter operated in positive ion mode. Spray and tube lens offset
voltages were set at 5 kV and 20 V, respectively. The capillary
voltage was set to 16 V (AM) or 3 V (AS and DHA). The
capillary temperature was 200°C, and sheath and auxiliary
gas (nitrogen) flow rates were 70 and 10 arbitrary units (AM)
or 50 and 10 arbitrary units (AS and DHA).
Mass spectra were measured and compared for the artemisinin
derivatives (Supplemental Figure 2) and their degradation prod-
ucts (Supplemental Figure 3), arising after forced degradation.
Several compounds that were hypothesized to result from the
degradation of ACTs were synthesized a priori including 9,10-
anhydroartemisinin, 2-deoxyartemisinin, β-AS, peroxyhemiacetal,
deoxy DHA, and α-AM.22,23 These products were analyzed by
LC–MS and considered as a match if both retention time and
mass spectra were the same as those of the unknown degrada-
tion products generated by the process of forced degradation.
Fractions identified to contain the degradation products were
collected using semi-preparative separation, freeze dried, and
used to identify degradation products in the “naturally aged”
ACTs as well as to test for antiplasmodial activity.
Antiplasmodial activity of degradation products. The anti-
plasmodial activity of the degradation products (D1–D4) result-
ing from the artemisinin derivatives were investigated in vitro
and compared with the activity of artemisinin standards (AS,
AM) using two recent African Plasmodium falciparum isolates,
according to standard methods described by van Schalkwyk
and others24 (Supplemental Information).
Differentiation of substandard and degraded ACTs from
Enugu. Samples of ACT tablets that had been recently pur-
chased for a drug quality survey in Enugu, and classified as
substandard after laboratory analyses for drug content19 were
reanalyzed using the LC–MS method developed here to inves-
tigate the presence of degradation products. Degradation
product profiles were used to differentiate between substan-
dard and degraded drugs. ACT tablets were kept at room
temperature and analyzed for degradation products within
4 weeks of analysis for drug content by HPLC–PDA.
RESULTS
Forced degradation studies. Blister packs of AS/AQ, AM/
LUM, and DHA/PIP tablets were subjected to degradation
in an oven at 60°C for up to 21 days and analyzed by
LC–MS. The resulting chromatograms were compared with
those obtained from the analysis of quality-assured tablets
that had not been subjected to degradation.
Degradation of AS/AQ tablets. Peaks corresponding to
the AS and AQ components (LC retention time 6.5 and
3.0 minutes, respectively) were identified in tablets before
and after degradation (Table 2, Figure 2A and B). In the
degraded tablets, additional peaks from two degradation
products of AS—D1 and D2 (retention times 4.7 and
8.3 minutes, respectively)—were detected by extracting chro-
matograms at m/z 221 and m/z 267, common signature ions
for fragments of fragile artemisinin derivatives (Table 2 and
Figure 2B).26,27 On comparison with standards of possible
degradation products, the only compound identified was
2-deoxyartemisinin (D2; Supplemental Figure 4). The API
content in the co-formulated AS/AQ tablets (bilayer tablets)
was monitored for 21 days. Although AQ content was stable
over this period, AS content decreased over time. Packaging
(intact or perforated) did not affect the amount of AQ,
whereas the amount of AS decreased more rapidly when the
packaging was intact compared with when the tablets were
exposed to the atmosphere in perforated packaging (Figure 3A).
Degradation of AM/LUM tablets. Before degradation, the
chromatograms (Table 2 and Figure 2C) were characterized
by peaks corresponding to LUM and AM (retention times
5.2 and 6.6 minutes, respectively). Additional peaks were
noted in the degraded tablets at retention times 3.2, 3.8, and
4.5 minutes (Table 2 and Figure 2C and D). The latter two
of these peaks (L1 and L2) were identified from the litera-
ture as LUM impurities.28–30 Only small amounts of AM
remained in the degraded tablets (Figure 2D); by extracting
chromatograms at m/z 221, four additional peaks were
observed, which were assigned to AM degradation products
D3–D6 (Figure 2D). The primary AM degradation product
TABLE 2
Summary of degradation products identified by liquid chromatography mass spectrometry after “forced degradation” of artemisinin-based com-
bination therapies in an oven at 60°C for up to 21 days
Formulation API (retention time) Degradant (retention time) Figure (chromatogram/spectrum)
AS/AQ Winthrop® AS (6.5 minutes);
AQ (3.0 minutes)
D1 (4.7 minutes); D2 (8.3 minutes) Figure 2A and B/Supplemental
Figures 2 and 3
AM/LUM Coartem® AM (6.6 minutes);
LUM (5.2 minutes)
L1 (3.8 minutes); L2 (4.5 minutes);
D3 (3.9 minutes); D4-D6 (4.0–5.2 minutes)
Figure 2C and D/Supplemental
Figures 2 and 3
DHA/PIP Waipa α-DHA (7.2 minutes);
β-DHA (9.3 minutes)
D2 (7.9 minutes); D3/D7 (4.5-5.5 minutes);
D8 (6.2 minutes); D9 (6.6 minutes)
Figure 2E and F/Supplemental
Figures 2 and 3
AM = artemether; API = active pharmaceutical ingredient; AS = artesunate; AQ = amodiaquine; DHA = dihydroartemisinin; LUM = lumefantrine; PIP = piperaquine.
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observed was D3 with a retention time of 3.9 minutes
(Table 2). On comparison with standards, the only com-
pounds identified were desbutylketo derivatives of LUM
(L1) and LUM-N-oxide (L2). Monitoring the API content
over time, showed LUM to be stable for 21 days, whereas
AM content decreased. Packaging (intact or perforated) did
not affect the AM or LUM content under forced degradation
(Figure 3B).
Degradation of DHA/PIP tablets. DHA is considered to be
the least stable artemisinin derivative formulated in ACTs.16,31
Before degradation (Figure 2E and Table 2), chromatographic
peaks were observed, which corresponded to the two epimers
of DHA (α- and β-DHA, retention times 7.2 and 9.3 minutes,
respectively). In addition, a further peak, accepted as an impu-
rity or degradation product of DHA, was observed (retention
time 6.3 minutes; Figure 2E). After forced degradation, the
DHA peaks diminished indicating the complete loss of this
API. A large peak was observed with an identical retention
time to α-DHA (Figure 2F); however, its mass spectrum
matched that of D2 and not DHA (Supplemental Figures 2
and 3). A further four peaks (Figure 2F) were detected; three
of these were assigned as DHA degradation products D7–D9
(Table 2). The fourth peak (retention time 5.0 minutes) had a
mass spectrum identical to that of D3 (Supplemental Figure 3),
also a product of AM degradation. By comparison with stan-
dards of possible degradation products, the only compound
identified was 2-deoxyartemisinin (D2). API content over time
was measured; as with previous ACTs, the partner drug PIP
did not change with time, whereas DHA content decreased
substantially. Packaging (intact or perforated) did not affect
the amount of DHA or PIP in these co-formulated DHA/PIP
tablets (Figure 3C).
Antiplasmodial activity. The antiplasmodial potency of
the major degradation products D1–D4 were tested against
FIGURE 2. Artemisinin-based combination therapies before and after “forced degradation” at 60°C. AS/AQ tablets analyzed by liquid chro-
matography mass spectrometry (LC–MS) before (A) and after (B) degradation. Degradation products D1 and D2 were observed by extracted
ion chromatograms (XIC) at m/z 221 and m/z 267. AM/LUM tablets analyzed by LC–MS before (C) and after (D) degradation. Degradation
products D3–D6 were observed for AM, while LUM degradation products L1 and L2 were identified as desbutylketo derivatives of LUM (L1)
and LUM-N-oxide (L2). DHA/PIP tablets analyzed by LC–MS before (E) and after (F) degradation. Degradation products D2, D3, and D7–D9
were observed by extracting chromatograms at m/z 221. AM/LUM = artemether/lumefantrine; AS/AQ = artesunate/amodiaquine; DHA/PIP =
dihydroartemisinin/piperaquine.
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P. falciparum parasites in vitro and compared with that of
AS and AM.24 The assays (Supplemental Table 1) revealed
that AS and AM exhibit potent antimalarial properties as
expected, whereas the degradation products D1–D4 and
2-deoxyartemisinin have an almost 1,000-fold or greater
reduction in antimalarial activity.
Natural aging: Stability of ACTs in tropical climatic
conditions. This study undertook to conduct natural aging
of two commonly used ACTs from WHO prequalified man-
ufacturers,25 AS/AQ and AM/LUM, over 3 years at tropical
temperature and humidity (Table 1). Tablets of each formula-
tion were naturally aged in two sites and under four storage
conditions (Figure 1), and their API content was monitored
with time.
The amount of partner drugs AQ and LUM in the co-
formulated AS/AQ and AM/LUM (Supplemental Figure 5)
was found to be stable for at least 3 years under the storage
conditions used (F8,315 < 1.96, P > 0.05). Similarly, the
ANOVA of AM concentrations revealed no significant differ-
ences between the start and end of the study (F8,315 = 1.73,
P > 0.05) for any of the storage groups. This suggests that
AM content did not vary over the duration of the study
or between different storage groups (Figure 4A and Supple-
mental Figure 6).
In contrast, a significant difference in AS content of the
AS/AQ tablets was observed between the different groups
at 36 months and the start of the study (F8,315 = 30.5, P <
0.001). Post hoc comparisons using the Tukey’s HSD test
revealed that significantly lower levels of AS (decrease of
5–7%) were measured at the end of the study for tablets
that had been stored in perforated blister packs (P < 0.001;
Figure 4D and Supplemental Figure 6), whereas other stor-
age groups did not differ significantly in their AS content
from the initial values. To further investigate the effect of
storage conditions on AS content after 36 months, a three-
factor ANOVA (site, lighting, and packaging) showed no
significant main effect for the site (LSHTM/Ghana) factor
(F1,280 < 1, nonsignificant [ns]), no significant main effect for
the lighting factor (F1,280 < 1, ns); however, the main effect
for the packaging factor (perforated/intact) was highly sig-
nificant (F1,280 = 62, P < 0.001). There were no significant
interaction effects.
Although the amount of AM did not change significantly
from its initial amount, the presence of a degradation prod-
uct was detected by MS in tablets after 36 months, albeit at
low levels, which was not present initially (Figure 4B and C).
Similarly, a degradation product was observed in naturally
aged AS/AQ tablets after 36 months (Figure 4E and F).
These degradation products had matching retention times and
mass spectra to those of D3 and D1, respectively, which were
also observed in the forced degradation study of AM/LUM
and AS/AQ tablets at 60°C.
Differentiation between substandard and degraded ACT
formulations purchased in Enugu. Samples of ACT tablets
purchased in Enugu, and previously found to be substandard
with APIs of < 85% were reanalyzed (N = 44) using LC–MS
to test for degradation products.19 Suspensions were excluded
from this reanalysis. The tablets of ACTs included various
AM/LUM brands (Amatem Forte®, Amatem Tab®, Arcofan,
Artrin®, Artemetrin®, Fynale, Ogamal, and Ogamal QS), one
AS monotherapy brand (Maltarka), and one DHA/PIP brand
(Droa-Quine®). Within the brands identified to contain degra-
dation products, 38 packages of 152 (25.0%) were found to
contain degraded tablets, six (3.9%) contained substandard
tablets, and 108 (71.1%) were of good quality (Table 3). The
only brands for which all the packages examined (although
in some cases we only had one package) and that contained
tablets with degradation products were Arcofan, Fynale,
Ogamal, and Droa-Quine®, whereas in other brands, a pro-
portion of the packages revealed evidence of products of deg-
radation (Table 3).
The major degradation products that were isolated from the
AM/LUM tablets after forced degradation were D3 and D4.
These degradation products were also observed in the majority
FIGURE 3. Degradation over time for “forced degradation” of artemisinin-based combination therapies. Forced degradation of (A) AS/AQ,
(B) AM/LUM, and (C) DHA/PIP tablets. Tablets were sampled twice a week, and the %API for the partner drugs (AQ, LUM, and PIP) and
artemisinin derivatives (AS, AM, DHA) was quantified using high-performance liquid chromatography photo diode array. Error bars show stan-
dard deviation (N = 3). AM/LUM = artemether/lumefantrine; %API = active pharmaceutical ingredient; AS/AQ = artesunate/amodiaquine;
DHA/PIP = dihydroartemisinin/piperaquine.
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of substandard AM/LUM field tablets (aka field samples)
from Enugu (two examples are shown in Figure 5A and B,
and further examples are provided in the Supplemental
Appendix). Two degradation products of LUM were also
detected, desbutylketo derivatives of LUM (L1) and LUM-
N-oxide (L2). In addition, package analysis revealed that
some of the tablets were discolored and/or there was presence
of a sticky residue (Figure 5C). Similarly, Droa-Quine® DHA/
TABLE 3
Proportion of acceptable quality, substandard, and degraded tablets in relation to brands of artemisinin-based combination therapies purchased
in Enugu, Nigeria
Brand Stated manufacturer Stated APIs Total no. of samples Acceptable quality (%) Substandard (%) Degraded (%)
Amatem Forte® Micro Labs Limited, India AM/LUM 43 97.7 0 2.3
Amatem Tab® 20/120 Micro Labs Limited, India AM/LUM 31† 71.0 12.9 16.1
Arcofan 20/120 Naxpar Laboratory Pvt. Ltd., India AM/LUM 15† 0 0 100.0
Artemetrin® 80/480 A.C. Drugs Ltd., Nigeria AM/LUM 5† 20.0 0 80.0
Artrin® Medreich Limited, India AM/LUM 15 73.3 0 26.7
Fynale Naxpar Laboratory Pvt. Ltd., India AM/LUM 1 0 0 100.0
Ogamal Vapi Care Pharma Pvt. Ltd., India AM/LUM 1† 0 0 100.0
Ogamal QS Vapi Care Pharma Pvt. Ltd., India AM/LUM 35 91.4 2.9 5.7
Maltarka Vapi Care Pharma Pvt. Ltd., India AS/S/P* 5 0 33.3 66.7
Droa-Quine® Hubei Meibao Pharmaceutical
Co. Ltd., China
DHA/PIP 1 0 0 100.0
Total 152 (100%) 71.1 3.9 25.0
ACTs = artemisinin-based combination therapies; AM = artemether; API = active pharmaceutical ingredient; AS = artesunate; DHA = dihydroartemisinin; LUM = lumefantrine; P = pyri-
methamine; PIP = piperaquine; S = sulfadoxine.
All manufacturers listed in Table 3 were non–World Health Organization prequalified.25
*Not co-formulated, that is, AS in one tablet with S/P in a second tablet.
†When purchased, all tablets except one package of Ogamal had not reached their expiry date; however, three other packages of tablets (Amatem Forte®, Arcofan 20/120, and Artemetrin® 80/480)
had exceeded their expiry date at the time of laboratory analysis. All the other tablets remained within date.
FIGURE 4. Long-term stability of artemisinin-based combination therapies in tropical climates. AM content in AM/LUM tablets (A) and AS con-
tent in AS/AQ tablets (D) was measured at 36 months after storing at high temperature and humidity in Ghana or a pharmaceutical stability chamber
(LSHTM). Error bars represent standard deviation (N = 36). AS/AQ tablets in perforated blister packs showed significantly lower levels of AS than
those in which the blister packaging was intact (*** P < 0.001). Tablets were analyzed by liquid chromatography mass spectrometry and representative
chromatograms are shown at the start (B, E) and end (C, F) of the study. Extracted chromatograms (m/z 221) show the presence of degradation prod-
uct D3 in aged AM/LUM and D1 in aged AS/AQ tablets. AM/LUM = artemether/lumefantrine; AS/AQ = artesunate/amodiaquine; DHA/PIP =
dihydroartemisinin/piperaquine; LSHTM = London School of Hygiene and Tropical Medicine.
998 HALL AND OTHERS
PIP tablets purchased in the field and determined to contain
a low %DHA by HPLC–PDA were reanalyzed by LC–MS
(Figure 5D) and found to contain DHA degradation product
D3 (matching retention time and mass spectrum).
DISCUSSION
This study demonstrates that the use of fingerprint chro-
matographic profiles obtained by subjecting tablets to forced
degradation can be used to facilitate the classification of
drugs as degraded. Furthermore, the forced degradation
study revealed that the artemisinin derivatives AS, AM, and
DHA degrade extensively when stored at 60°C for up to
21 days, while partner drugs AQ, LUM, and PIP were stable
under these conditions. The integrity of the packaging, that
is, whether the blister pack was perforated or intact, did not
affect the forced degradation of AM and DHA; however,
AS degraded more rapidly in the intact blister packs. The
instability of AS (dihydroartemisinin-10α-hemisuccinate) in
the presence of AQ (present here as the dihydrochloride
salt) is well documented, particularly at high heat and
humidity.32,33 In this forced degradation study, moisture was
noticed to be retained in the intact blisters, whereas tablets
stored in perforated blister packs were found to be dry and
brittle. One of the main degradation products of AS was
identified as 2-deoxyartemisinin, but the identity of the other
products is beyond the scope of this study. Degradation
products were isolated and found to have negligible anti-
plasmodial potency against two recent African isolates of
P. falciparum, indicating that severely degraded ACTs will
be ineffectual for malaria treatment.
Tablets of Coartem AM/LUM and Winthrop AS/AQ (com-
mon brands of ACTs from WHO prequalified manufacturers)
were found to be stable when naturally aged under tropical
conditions. Acceptable levels of all APIs (90–110% as per
International Pharmacopeia tolerance limits) were measured
over 3 years, despite drugs having reached their expiry dates
18 to within 24 months from the start of the study. This sug-
gests that the shelf life of AM/LUM and AS/AQ could be
reevaluated in an effort to improve the cost-effectiveness of
the treatment in the poorest countries.34 Although no signifi-
cant degradation was observed for AM, LUM, and AQ over
the study period, low levels of degradation (< 7%) for AS
was measured for tablets stored in perforated blister packs.
This suggests that the degradation for AS in co-formulated
AS/AQ tablets is higher when the tablets are exposed directly
(perforated blisters) to conditions of high heat and humidity.
Low levels of degradation products could be detected in tab-
lets from both ACT formulations after 18 months, demon-
strating that the LC–MS method reported here is a sensitive
and robust approach to establish the presence of degradation
products in ACTs, even before substantial loss of the API
has occurred. Reanalyses of the tablets from Enugu, initially
classified as substandard (when they contained < 85% APIs),
revealed 25.0% to be degraded (Table 3), suggesting that
FIGURE 5. Comparing degraded tablets (field samples) with artificially degraded tablets. Liquid chromatography mass spectrometry (LC–MS)
analysis of AM/LUM Arcofan (A) and Amatem Tab® (B) tablets revealed similar degradation products to artificially degraded AM/LUM tablets
(“forced degradation”). Extracted ion chromatograms for m/z 221 (signature fragment ion) are shown below the total ion chromatogram. Exami-
nation of the Arcofan packaging revealed a sticky residue on the inside of the blister packs (C). LC–MS analysis of Droa-Quine® DHA/PIP
tablet revealed the presence of degradation product D3 (D). AM/LUM = artemether/lumefantrine; DHA/PIP = dihydroartemisinin/piperaquine.
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degradation of ACTs may account for a high proportion of
drugs previously classified as substandard or indeed those
suspected to be falsified since several degraded AM/LUM
field samples had no detectable amounts of AM (although
levels of LUM were within the acceptable range).
The natural aging study indicates that quality-assured
drugs from WHO prequalified manufacturers are stable in
tropical climates for periods up to and well beyond their
expiry dates. However, some brands of tablets purchased in
Enugu reclassified to be degraded were from non-WHO
prequalified manufacturers. This observation warrants further
investigation to determine if all brands of ACTs are stable in
tropical climates.
CONCLUSION
Poor quality medications are of great concern and may
include falsified, substandard, and degraded drugs. In this
study, three common ACTs were subjected to forced degrada-
tion and an LC–MS method was developed to aid the differ-
entiation of substandard and degraded drugs. Application of
this method to a large number of tablets purchased in Enugu
revealed that degradation was one of the major hitherto not
recognized causes of drugs failing chemical content analysis.
These degraded ACTs were from manufacturers without
WHO prequalification status. However, our findings in a
large-scale natural aging study showed that quality-assured
ACTs from WHO prequalified manufacturers were stable in
tropical conditions of high temperature and humidity for over
3 years, despite drugs reaching their expiry dates before the
end of the study. This stability was also observed within the
ACTs purchased in Enugu, which were stated to be from
WHO prequalified manufacturers. Although these findings
cannot be generalized, they do warrant further investigation
of drug stability in a variety of settings in malaria-endemic
countries. Furthermore, manufacturers are to be encouraged
to attain WHO prequalification status, and follow-up studies
are warranted to uncover factors that may have an impact
on drug stability. Degraded drugs should be differentiated
from substandard drugs as those that do not comply with the
pharmacopeia-specified acceptance criteria of containing less
than the acceptable API content and in which products of
degradation are detected.
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